Profile data is unavailable for this security.
About the company
Oncoarendi Therapeutics SA is a Poland-based biopharmaceutical company . The Company is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Company's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The Company has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
- Revenue in PLN (TTM)1.31m
- Net income in PLN-18.31m
- Incorporated2017
- Employees111.00
- LocationMolecure SAZwirki I Wigury 101WARSZAWA 02-089PolandPOL
- Phone+48 225526724
- Websitehttps://molecure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urteste SA | 0.00 | -5.59m | 132.51m | -- | -- | 4.78 | -- | -- | -4.52 | -4.52 | 0.00 | 19.68 | 0.00 | 3.86 | -- | -- | -30.78 | -- | -32.71 | -- | -- | -- | -- | -- | 17.11 | -- | 0.0221 | -- | -100.00 | -- | -37.59 | -- | -- | -- |
| Sds Optic SA | 530.40k | -7.39m | 134.01m | -- | -- | 19.11 | -- | 252.65 | -1.30 | -1.30 | 0.0928 | 1.19 | 0.054 | -5.91 | 2.11 | -- | -75.38 | -- | -94.39 | -- | 167.64 | -- | -1,395.87 | -- | 4.85 | -- | 0.00 | -- | -99.59 | -- | -85.26 | -- | -- | -- |
| Genomtec SA | 1.00k | -9.01m | 154.45m | -- | -- | 18.60 | -- | 154,449.40 | -0.8037 | -0.8037 | 0.00009 | 0.6773 | 0.00007 | 15.45 | 0.0008 | -- | -65.01 | -- | -80.98 | -- | -81,000.00 | -- | -901,300.00 | -- | 2.11 | -46.67 | 0.1613 | -- | -97.50 | -- | 24.44 | -- | -- | -- |
| Poltreg SA | 1.40m | -13.55m | 219.65m | 23.00 | -- | 2.51 | -- | 157.00 | -2.91 | -2.91 | 0.300 | 18.77 | 0.0112 | 51.22 | 27.43 | 61,494.50 | -10.82 | -6.51 | -12.42 | -7.35 | -811.65 | -391.38 | -968.62 | -449.24 | 3.87 | -- | 0.0856 | -- | 40.04 | -- | -588.92 | -- | 214.26 | -- |
| Molecure SA | 1.31m | -18.31m | 246.48m | 111.00 | -- | 1.57 | -- | 188.36 | -1.17 | -1.17 | 0.0847 | 9.34 | 0.0085 | -- | 0.2818 | 11,788.92 | -11.94 | 2.52 | -12.47 | 2.64 | -25.76 | 97.54 | -1,398.86 | 12.84 | -- | -- | 0.0434 | -- | -18.85 | 237.24 | -19.67 | -- | -24.82 | -- |
| Bioceltix SA | 0.00 | -12.73m | 282.46m | -- | -- | 19.85 | -- | -- | -3.45 | -3.45 | 0.00 | 3.45 | 0.00 | 170.52 | -- | -- | -112.58 | -- | -140.07 | -- | -- | -- | -- | -- | 5.96 | -- | 0.0071 | -- | -- | -- | -102.87 | -- | -- | -- |
| Mabion SA | 146.11m | 42.34m | 297.06m | 226.00 | 7.02 | 2.20 | 5.98 | 2.03 | 2.62 | 2.62 | 9.04 | 8.37 | 0.7084 | 4.59 | 8.27 | 646,495.60 | 20.53 | -7.19 | 28.38 | -16.79 | 75.66 | 58.10 | 28.98 | -14.27 | 1.93 | 25.96 | 0.1513 | -- | -7.50 | -- | 77.94 | -- | 40.86 | -- |
| BIOTON SA | 181.64m | 2.28m | 304.82m | 358.00 | 134.01 | 0.5027 | 8.18 | 1.68 | 0.0265 | 0.0265 | 2.12 | 7.06 | 0.2228 | 0.9493 | 18.41 | 507,363.10 | 0.279 | -1.99 | 0.3437 | -2.47 | 40.11 | 45.33 | 1.25 | -8.61 | 0.2933 | 1.90 | 0.1018 | -- | -22.10 | -5.51 | 60.10 | -38.69 | 0.3284 | -- |
| Captor Therapeutics SA | 13.20m | -70.58m | 320.75m | 104.00 | -- | 5.10 | -- | 24.30 | -16.42 | -16.42 | 3.04 | 14.90 | 0.1256 | -- | 3.59 | 126,932.70 | -67.13 | -- | -82.96 | -- | 52.28 | -- | -534.69 | -- | -- | -- | 0.0518 | -- | 44.15 | -- | -96.65 | -- | -- | -- |
| Synthaverse SA | 58.61m | 4.76m | 329.57m | 239.00 | 74.57 | 3.15 | 28.94 | 5.62 | 0.0677 | 0.0677 | 0.8341 | 1.60 | 0.2732 | 1.66 | 2.76 | 245,217.60 | 2.22 | 3.53 | 2.55 | 4.32 | 60.00 | 55.62 | 8.12 | 9.59 | 0.9705 | 4.47 | 0.3834 | -- | 16.32 | 12.66 | -21.76 | -- | 111.77 | -- |
Data as of May 17 2024. Currency figures normalised to Molecure SA's reporting currency: Polish New Zloty PLN
10.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nationale-Nederlanden PTE SAas of 30 Jun 2023 | 845.00k | 5.02% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 498.67k | 2.96% |
| Allianz Polska TFI SAas of 31 Dec 2023 | 327.84k | 1.95% |
| Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 31 Dec 2022 | 55.16k | 0.33% |
| Rockbridge TFIas of 30 Jun 2023 | 6.04k | 0.04% |
| Millennium TFI SAas of 30 Jun 2020 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2020 - 31 Mar 2024Source: FactSet Research Systems Inc.
